Gilead Sciences (NASDAQ: GILD) reports $1.94B in 13F holdings
Filing Impact
Filing Sentiment
Form Type
13F-HR
Rhea-AI Filing Summary
Gilead Sciences filed a Form 13F Holdings Report disclosing its institutional holdings. The filing lists 6 reported holdings with a combined market value of $1,935,507,854. The report was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, on 02-12-2026.
Positive
- None.
Negative
- None.
FAQ
What does GILD's Form 13F filed on 02-12-2026 disclose?
The Form 13F discloses institutional holdings as a 13F Holdings Report. It lists 6 holdings totaling $1,935,507,854 in market value, and the filing was signed by Andrew D. Dickinson on 02-12-2026.
How many holdings and what total value are reported for Gilead (GILD)?
The filing reports 6 holdings with a combined value of $1,935,507,854. This figure is the Form 13F Information Table Value Total, rounded to the nearest dollar, as shown on the report summary.
Who signed Gilead's Form 13F and what is their title?
The Form 13F was signed by Andrew D. Dickinson, whose title is Executive Vice President and Chief Financial Officer. The signature block lists his telephone number and the signing location as Foster City, California.
Does Gilead's 13F include other included managers?
Yes; the report summary lists 1 other included manager. The List of Other Included Managers names Gilead Therapeutics A1 Unlimited Co with Form 13F File No. 028-25083.
Is this filing a full 13F Holdings Report or a notice/combination?
This submission is marked as a 13F HOLDINGS REPORT, indicating that all holdings of this reporting manager are reported in this report, as checked on the Report Type line of the cover page.